USD 3.12
(-11.36%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 84.22 Million USD | -8.66% |
2022 | 92.21 Million USD | -25.8% |
2021 | 124.27 Million USD | -75.59% |
2020 | 509.12 Million USD | 3222.17% |
2019 | 15.32 Million USD | 156.92% |
2018 | 5.96 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 83.44 Million USD | 5.91% |
2024 Q1 | 80.28 Million USD | -4.67% |
2024 Q2 | 78.78 Million USD | -1.86% |
2023 Q2 | 86.88 Million USD | 1.58% |
2023 FY | 84.22 Million USD | -8.66% |
2023 Q1 | 85.53 Million USD | -7.24% |
2023 Q4 | 84.22 Million USD | 9.66% |
2023 Q3 | 76.8 Million USD | -11.6% |
2022 Q2 | 109.94 Million USD | -10.43% |
2022 Q1 | 122.75 Million USD | -1.22% |
2022 FY | 92.21 Million USD | -25.8% |
2022 Q4 | 92.21 Million USD | -7.44% |
2022 Q3 | 99.62 Million USD | -9.39% |
2021 FY | 124.27 Million USD | -75.59% |
2021 Q1 | 211.31 Million USD | -58.49% |
2021 Q4 | 124.27 Million USD | -3.71% |
2021 Q3 | 129.05 Million USD | -30.21% |
2021 Q2 | 184.91 Million USD | -12.5% |
2020 FY | 509.12 Million USD | 3222.17% |
2020 Q4 | 509.12 Million USD | 350.35% |
2020 Q3 | 113.05 Million USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q1 | - USD | -100.0% |
2019 Q4 | 15.32 Million USD | 0.0% |
2019 FY | 15.32 Million USD | 156.92% |
2018 FY | 5.96 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Abbott Laboratories | 34.38 Billion USD | 99.755% |
Allurion Technologies Inc. | 142.19 Million USD | 40.772% |
Artivion, Inc. | 510.61 Million USD | 83.506% |
Avanos Medical, Inc. | 456.1 Million USD | 81.535% |
Butterfly Network, Inc. | 84.22 Million USD | 0.0% |
Bio-Rad Laboratories, Inc. | 3.55 Billion USD | 97.633% |
Boston Scientific Corporation | 15.6 Billion USD | 99.46% |
Perspective Therapeutics, Inc. | 3.44 Million USD | -2341.896% |
CONMED Corporation | 1.46 Billion USD | 94.254% |
Edwards Lifesciences Corporation | 2.64 Billion USD | 96.814% |
Paragon 28, Inc. | 162.95 Million USD | 48.317% |
Glaukos Corporation | 478.64 Million USD | 82.404% |
Globus Medical, Inc. | 1.08 Billion USD | 92.26% |
Inspire Medical Systems, Inc. | 104.29 Million USD | 19.249% |
Integer Holdings Corporation | 1.41 Billion USD | 94.041% |
Medtronic plc | 39.56 Billion USD | 99.787% |
Nevro Corp. | 330.31 Million USD | 74.503% |
Owlet, Inc. | 73.79 Million USD | -14.122% |
Penumbra, Inc. | 377.36 Million USD | 77.682% |
Vicarious Surgical Inc. | 21.89 Million USD | -284.659% |
Smith & Nephew plc | 4.77 Billion USD | 98.234% |
Sonendo, Inc. | 49.74 Million USD | -69.319% |
STERIS plc | 4.74 Billion USD | 98.226% |
Stryker Corporation | 21.31 Billion USD | 99.605% |
Vapotherm, Inc. | 132.95 Million USD | 36.653% |
Zimmer Biomet Holdings, Inc. | 9 Billion USD | 99.065% |